Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UroGen Pharma Ltd. Director's Dealing 2021

Apr 22, 2021

32312_dirs_2021-04-22_8a3d4bc0-6973-4170-96cd-634ebee3764f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2021-03-24

Reporting Person: Belldegrun Arie (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-03-24 Ordinary Shares M 3241 $5.00 Acquired 245452 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-03-24 Stock Option (right to buy) $5.00 M 3241 Disposed 2021-07-27 Ordinary Shares (3241) Direct